Superworth

Bio-Rad Laboratories EV/EBIT BIO

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2011.

Today, Nov 2, 2026
39.7×
10-year median
31.1×
Against its 10-year history
69th
percentile: 0 is its lowest day, 100 its highest
10-year range
16.0× to 71.0×
Peer median
30.5×

Bio-Rad Laboratories' EV/EBIT is 39.7× as of Nov 2, 2026.

That is above its ten-year median of 31.1×, higher than on 69% of days in the last ten years.

Over that time it ranged from 16.0× in Oct 2022 to 71.0× in Nov 2017.

The median for 10 diagnostics and research stocks of a similar size is 30.5×.

EV/EBIT over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far39.7×25.4×42.3×
202535.6×21.8×40.3×
202428.9×22.1×32.4×
202324.5×20.1×30.2×
202221.8×16.0×33.2×
202138.2×36.5×63.1×
202055.1×19.4×67.5×
201920.3×16.9×20.6×
201862.0×57.8×67.3×
201758.3×34.8×71.0×
201634.0×19.2×34.2×
201521.6×17.7×22.1×
201418.8×17.1×21.1×
201318.7×10.6×18.7×
201210.1×8.9×10.5×
20118.8×8.2×9.4×

Against its peers

Companies in Medical - Diagnostics & Research nearest Bio-Rad Laboratories' size, closest first, today.

CompanyEV/EBIT
BIOBio-Rad Laboratories39.7×
CAICaris Life Sciences56.6×
LNTHLantheus20.8×
RVTYRevvity44.2×
MEDPMedpace30.4×
BLLNBillionToOne110×
CDNACareDx37.7×
VCYTVeracyte27.9×
DGXQuest Diagnostics19.0×
LHLabcorp22.9×
MTDMettler-Toledo International30.6×
Peer median30.5×

Where Bio-Rad Laboratories ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Bio-Rad Laboratories

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.